# Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

Study · id `cardio:ct-nct04419337` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04419337](<https://clinicaltrials.gov/study/NCT04419337>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04419337

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04419337. Randomized; no masking; primary purpose treatment. Start 2019-09-15 (actual); primary completion 2023-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04419337, source copy `cardio:ctgov-nct04419337-2023-03-30`, retrieved 2026-10-26)
- Started: 2019-09-15 (actual) (ClinicalTrials.gov record NCT04419337, source copy `cardio:ctgov-nct04419337-2023-03-30`, retrieved 2026-10-26)
- Primary completion: 2023-07-31 (anticipated) (ClinicalTrials.gov record NCT04419337, source copy `cardio:ctgov-nct04419337-2023-03-30`, retrieved 2026-10-26)
- Completion: 2024-01-31 (anticipated) (ClinicalTrials.gov record NCT04419337, source copy `cardio:ctgov-nct04419337-2023-03-30`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT04419337, source copy `cardio:ctgov-nct04419337-2023-03-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04419337-2023-03-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke
- Condition: Diabetes Mellitus
- Condition: Stroke
- Intervention (Drug): Metformin plus Pioglitazone plus an SGLT2 inhibitor
- Lead sponsor: Chang Gung Memorial Hospital
- Lead sponsor class: OTHER
- Collaborator: National Taiwan University Hospital
- Collaborator class: OTHER
- Collaborator: Chiayi Christian Hospital
- Collaborator class: OTHER
- Collaborator: Tainan Sin-lau Hospital
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Chang Gung Memorial Hospital (`cardio:org-chang-gung-memorial-hospital`)
- Registry lists this organization as a collaborator: National Taiwan University Hospital (`cardio:org-national-taiwan-university-hospital`)
- Registry lists this organization as a collaborator: Chiayi Christian Hospital (`cardio:org-chiayi-christian-hospital`)

## Provenance

Content hash: 6891a8d00344fc5c74de9317ea0cfda3f885be25a1c66257f2e7e88b3943ce2e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
